Sign in Get in touch
World risk · Trade, tariffs and sanctions · US trade & foreign policy

The US raises its tariff on UK goods above 10% or ends the UK's zero drug rate

The test Between 26 Oct 2026 and 25 Oct 2027, the US raises the Section 301 rate on products of the United Kingdom above 10%, or raises the additional Section 232 duty on UK patented medicines above zero, by a notice in force for at least one day.

Not under way · Confidence: medium · Reviewed 25 Oct 2026 · Scores from 1 to 10

This page answers: What could happen, how it is scored, and who is exposed?

Using this page
  1. Read the two scores: Likelihood and Impact are kept apart.
  2. Check what is happening, each fact with its source.
  3. Use the calendar for the dates to watch.

Follow this riskSign in to follow; one weekly email if you ask for it.

Likelihood
3Low steady this month
Impact
4Elevated steady this month
Breadth4
Depth4
Duration5
Hard to substitute4
Canada pointNot added0

Impact is the average of the four parts, rounded, plus one point when Canada is directly hit on two or more channels, up to 10.

Two separate scales from 1 to 10. Strature never multiplies or merges them.

What changed

Dated, newest first

  1. HTS 9903.04.63, UK patented pharmaceutical articles: applicable duty +0% [3]
  2. US imports from the UK US$64.8bn in 2025, US$44.1bn Jan-Aug 2026 [7]
  3. PM-Trump call 23 Oct 2026: Ukraine, nuclear, Jackdaw, Falklands, Saudi Arabia; no trade item in the readout [9]
  4. French customs: Section 122 10% expired 24 Jul 2026; trade court judgments 4 and 27 Mar 2026; Section 232 goods exempt from Section 301; UK steel 25%/15% under melt-and-cast rules; UK drug line still shown at 10% [4]
  5. UK car quota 100,000 a year at 10%, 25% above; Canada imported C$9.95bn from the UK in 2025 [8]
  6. UK listed among 19 jurisdictions eligible for the clause 3(d) zero-tariff adjustment for specialty drugs [10]

Why it matters

Since 24 Jul 2026 UK goods outside Section 232 have paid a 10% US Section 301 duty, the lower of the two tiers USTR set for 60 economies. UK patented medicines pay no extra US duty under Section 232, a country rate the proclamation ties to the UK alone and to the UK's December 2025 drug-pricing deal. Both rates can be raised by notice, but no US threat to do so has been found.

Why Likelihood 3 Pushes: clause 3(f) lets Commerce raise drug rates; US tariff volatility. Brakes: the December 2025 pricing deal and the pledge of no Section 301 case on UK drug pricing this term; the UK's lower tier; a friendly leaders' call on 23 Oct 2026. A driver exists but is blocked. Likelihood scores the Section 301 limb.

Why Impact 4 Threshold case a rise from 10% to 12.5%.

The other facts on file (4)
  • Section 301 notice: 60 economies; 10% tier (ban, partial ban, or reciprocal-deal commitment) and 12.5% for others; from 24 Jul 2026; UK at 10% for a partial regime, not net of MFN; rates appropriate 'at this time' [1] (28 Jul 2026)
  • Proclamation 11020: UK patented medicines 10%, reduced to zero to the extent required by a pricing deal; EU, Japan, South Korea, Switzerland 15%; applies from 31 Jul 2026 (Annex III companies) or 29 Sep 2026 (others); clause 3(f) allows increases [2] (2 Apr 2026)
  • 1 Dec 2025 deal: UK net prices for new medicines +25%; VPAG 15%; no US Section 301 case on UK drug pricing during this presidential term [5] (3 Dec 2025)
  • USTR stated the UK deal had been finalised [6] (6 Apr 2026)

Where it sits

11. The US raises its tariff on UK goods above 10% or ends the UK's zero drug rate: Elevated impact · unlikely1 · Elevated impact · unlikelyOttawaMexico CityCANADAMEXICOUNITED STATESPACIFIC OCEANATLANTIC OCEANGULF OF MEXICO01000 kmat 40°NMap data: Natural Earth (public domain).
11. The US raises its tariff on UK goods above 10% or ends the UK's zero drug rate: Elevated impact · unlikelyWashingtonCANADAMEXICOUNITED STATESGULF OF MEXICO0500 kmat 40°NMap data: Natural Earth (public domain).

How it spreads

If

Between 26 Oct 2026 and 25 Oct 2027, the US raises the Section 301 rate on products of the United Kingdom above 10%, or raises the additional Section 232 duty on UK patented medicines above zero, by a notice in force for at least one day.

Not under way

Channels 4 on the card

  1. CanadaNo Canadian loss sourced; Canada's C$9.95bn of UK imports in 2025 [8] are not touched.
  2. UK exportersA move from the 10% tier to the 12.5% tier adds 2.5 points on goods outside Section 232 [1].
  3. UK drug exports and the NHS dealEnding the zero rate removes the main gain the UK took for higher NHS drug prices.
  4. Trade policyThe 10% tier [1] and the pricing deal [5] would no longer be floors.

Who is exposed

Countries
United Kingdom, United States

Three scenarios and their signposts

  1. S1

    Steady

    Both rates hold.

  2. S2

    Tier shift

    USTR revisits the tiers and moves the UK to 12.5% over its partial forced-labour regime.

  3. S3

    Drug clawback

    Washington finds the UK short on prices or rebates and uses clause 3(f).

The signposts of each scenario
PathSignpost
S1No USTR or Commerce notice on the UK by mid-2027
S2A USTR review of forced-labour commitments
S3A US complaint on NHS prices or VPAG

No probability is given for the three paths.

Dates to watch

Calendar

The dates to watch

A dot is a day, a bar a month or a year; a hollow mark is tentative. The line marks today.

  1. Apr 2027 Commerce Secretary to inform the President on generic drug imports (within one year of 2 Apr 2026) [2] Declared · Outside event
SourceStrature world-risk card; the dates cite the sources below.
Exhibit R-3 · UNITED KINGDOM · strature.net

The other side

The UK holds the lowest US country rate for drugs in the proclamation [2][3] and the lower Section 301 tier [1]. That leaves UK-made medicines cheaper to ship to the US than EU, Swiss or Japanese ones.

Connected in Strature

Sources

10 sources, numbered as the text cites them

  1. Notice of Actions in Section 301 Investigations of Acts, Policies, and Practices of Various Economies Related to the Failure of Each Economy To Impose and Effectively Enforce a Prohibition on the Importation of Goods Produced With Forced Labor (2026-15181). USTR, Federal Register · 28 Jul 2026 · Official · confidence high · retrieved 26 Oct 2026
  2. Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients into the United States (Proclamation 11020). The White House · 2 Apr 2026 · Official · confidence high · retrieved 26 Oct 2026
  3. Harmonized Tariff Schedule, heading 9903.04.63. US International Trade Commission · 26 Oct 2026 · Official · confidence high · retrieved 26 Oct 2026
  4. US tariffs: US and EU tariff measures in force. French customs (DGDDI) · 20 Oct 2026 · Official · confidence medium · retrieved 26 Oct 2026
  5. U.S. Exempts UK Pharmaceuticals from Section 232 Tariffs. GHY International · 3 Dec 2025 · Industry · confidence medium · retrieved 26 Oct 2026
  6. Trade Winds Shift for Pharma: Understanding the Section 232 Tariff Proclamation on Pharmaceuticals. Arnold & Porter · 6 Apr 2026 · Industry · confidence medium · retrieved 26 Oct 2026
  7. Trade in Goods with United Kingdom. US Census Bureau · 26 Oct 2026 · Official · confidence high · retrieved 26 Oct 2026
  8. United Kingdom dossier, rows GBR-us-tariffs-canada-eur-3 and GBR-us-tariffs-canada-eur-1. Strature library (Federal Register; Statistics Canada) · 6 Oct 2026 · Official · confidence high · retrieved 25 Oct 2026
  9. PM call with President Trump of the United States: 23 October 2026. GOV.UK (Prime Minister's Office) · 23 Oct 2026 · Official · confidence high · retrieved 26 Oct 2026
  10. Guidance and Procedures for Implementing Tariff Adjustments for Specialty Pharmaceuticals under Proclamation 11020 (2026-19498). Bureau of Industry and Security, Federal Register · 23 Sep 2026 · Official · confidence high · retrieved 26 Oct 2026

Reviewed 25 Oct 2026 · version 1 · last change: reviewed · All risks